ArticleOncotarget2015
Novel insights into Notum and glypicans regulation in colorectal cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 67 citations in OpenAlex.
- Structurally exclusive Teneurin complexes orchestrate divergent programs in early cortical development.Nature communications · 2026Article
- Article
- Article
- Azoxymethane/Dextran Sodium Sulfate (AOM/DSS) Model of Colorectal Cancer.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action.Exploration of targeted anti-tumor therapy · 2024Article
- Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients.Scientific reports · 2023Article
- Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity.European journal of medicinal chemistry · 2023Article
- Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing.Frontiers in oncology · 2023Article
- Promotion of colorectal cancer by transcription factor BHLHE40 involves upregulation ofFrontiers in oncology · 2023Article
- Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit.Journal of medicinal chemistry · 2022Article
- Review
- GPC1 Is Associated with Poor Prognosis and Treg Infiltration in Colon Adenocarcinoma.Computational and mathematical methods in medicine · 2022Article
- Small-molecule inhibitors of carboxylesterase Notum.Future medicinal chemistry · 2021Review
- Article
- Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.BMC cancer · 2021Article
- Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling.Journal of medicinal chemistry · 2021Article
- Molecular features and gene expression signature of metastatic colorectal cancer (Review).Oncology reports · 2021Review
- Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy.International journal of molecular sciences · 2021Review
- Right and left-sided colon cancers - specificity of molecular mechanisms in tumorigenesis and progression.BMC cancer · 2020Article
- The olfactory G protein-coupled receptor (Olfr-78/OR51E2) modulates the intestinal response to colitis.American journal of physiology. Cell physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The connection between colorectal cancer (CRC) and Wnt signaling pathway activation is well known, but full elucidation of the underlying regulation of the Wnt/β-catenin pathway and its biological functions in CRC pathogenesis is still needed. Here, the azoxymethane/dextran sulfate sodium salt (AOM/DSS) murine model has been used as an experimental platform able to mimic human sporadic CRC development with predictable timing. We performed genome-wide expression profiling of AOM/DSS-induced tumors and normal colon mucosa to identify potential novel CRC biomarkers. Remarkably, the enhanced expression of Notum, a conserved feedback antagonist of Wnt, was observed in tumors along with alterations in Glypican-1 and Glypican-3 levels. These findings were confirmed in a set of human CRC samples. Here, we provide the first demonstration of significant changes in Notum and glypicans gene expression during CRC development and present evidence to suggest them as potential new biomarkers of CRC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.